Aim immunotech inc. (HEB)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Sep'12Jun'12Mar'12Sep'11Jun'11Mar'11Sep'10Jun'10
Revenues:
Total revenues

0

-

0

0

-

367

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Clinical treatment programs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

0

0

-

0

0

Total Revenues

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

0

0

-

0

0

Clinical treatment programs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total revenues

-

-

-

-

-

-

-

-

-

-

-

-

137

92

103

104

136

133

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Costs and expenses:
Production costs

866

893

958

936

907

884

898

1,089

1,121

1,183

1,165

1,038

1,110

1,108

1,196

1,277

1,494

1,598

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Production

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

0

0

-

0

0

Research and development

4,621

4,651

4,201

4,606

4,851

4,778

4,605

3,797

3,562

4,098

5,147

5,702

5,496

5,107

4,201

4,827

6,366

8,038

9,519

9,445

9,336

8,988

8,083

8,362

8,350

8,360

0

0

0

-

-

-

0

0

-

0

0

General and administrative

7,540

7,039

7,187

6,614

6,405

6,201

6,302

6,585

6,471

6,572

6,799

6,877

6,897

7,681

7,268

7,319

7,682

7,147

7,447

7,936

8,431

9,057

8,969

8,865

8,185

7,723

0

0

0

-

-

-

0

0

-

0

0

Total costs and expenses

13,027

12,583

12,346

12,156

12,163

11,863

11,805

11,471

11,154

11,853

13,111

13,617

13,503

13,896

12,665

13,423

15,542

16,783

18,526

18,894

19,067

19,296

18,131

18,252

17,901

17,317

0

0

0

-

-

-

0

0

-

0

0

Operating loss

-12,842

-12,443

-12,016

-11,849

-11,852

-11,496

-11,628

-11,242

-10,745

-11,416

-12,708

-13,282

-13,366

-13,804

-12,562

-13,319

-15,406

-16,650

-18,380

-18,726

-18,910

-19,099

-17,938

-18,068

-17,717

-17,167

0

0

0

-

-

-

0

0

-

0

0

Interest and other income

98

89

23

5

40

32

0

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Impairment loss on investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

Interest expense and other finance costs

503

427

787

653

609

502

322

314

278

139

0

0

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Convertible note valuation adjustment

-

-

0

0

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest and other income

-

-

-

-

-

-

-

-

-

-

-

60

94

129

177

318

319

364

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Settlement of litigation/Insurance Claim

-

-

-

0

-

-

-

0

-

-

0

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Debt discount associated with extinguished debt

-

345

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Fair value of convertible note adjustment

-

-

-

-

0

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

0

0

-

0

0

Interest and other income/expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

0

0

-

0

0

Redeemable warrants valuation adjustment

-1,373

-1,510

-1,824

-2,074

-1,351

-1,165

-884

-1,626

-1,793

-2,417

-3,934

-2,599

-2,070

-1,677

-103

0

0

-

0

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Settlement with vendor

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Litigation settlement net insurance proceeds

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain from sale of income tax operating losses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,374

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on sale of building

-

-

-

-

-

223

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain (loss) on sale of marketable securities

-

-

-

0

-

-

0

0

-

-

0

0

0

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain from sale of income tax net operating losses and research credits

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-9,976

-9,533

-9,963

-10,093

-10,479

-9,827

-10,199

-8,373

-8,151

-8,259

-7,439

-9,049

-8,159

-7,502

-9,466

-10,407

-13,949

-15,230

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other comprehensive (loss) income:
Unrealized loss on marketable securities

0

-

-

0

-

-

-44

-42

9

33

-17

-13

7

35

-159

-174

-212

-252

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized loss on marketable securities

-

-

-

0

-

-

0

-

-

-17

-26

-57

-51

57

632

448

311

315

0

0

0

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

Net comprehensive loss

0

-

-9,933

-10,055

0

-

-10,254

-8,425

-8,158

-8,243

-7,482

-9,119

-8,203

-7,410

-8,993

-10,133

-13,850

-15,167

0

0

0

-

-

-

-

-

-

-

-

-

-

-

0

-

-

0

-

Gain from sale of income tax net operating losses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

Funds received from sale of income tax net operating losses (Note 15)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

0

-

Funds received from sale of income tax net operating losses (Note 13)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

0

Redeemable warrants valuation adjustment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

0

0

-

0

0

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

0

0

-

0

0

Unrealized gain (loss) on marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

0

0

-

-

-

0

-

-

0

-

Reclassification adjustments for impairment losses included in net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

Reclassification adjustments for impairment losses included in net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

Net comprehensive loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

Basic and diluted loss per share

-0.22

2.49

-1.13

-1.07

-2.91

-4.45

-2.87

-2.38

-0.07

-0.06

-0.04

-0.08

-0.11

-0.05

-0.13

-0.06

-0.10

-0.55

-0.18

-0.02

-0.02

-1.04

-0.02

-0.03

-0.02

-0.02

-0.03

-0.03

-0.02

-

-

-

-0.02

-0.02

-

-0.02

-0.01

Weighted average shares outstanding, basic and diluted

17,490

8,911

2,603

1,898

1,156

-34,339

1,072

1,015

36,269

31,960

30,096

27,306

25,341

24,142

21,832

20,667

20,630

-391,631

20,564

236,149

213,634

-490,394

190,677

185,749

176,730

167,903

167,389

167,202

166,806

-

-

-

-

-

-

-

-

Stock issued for settlement of accounts payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

Equity-based compensation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

0

-

-

Net comprehensive loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

0

-

-

Weighted average shares outstanding basic and diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

135,496

135,375

-

134,869

133,107

United States [Member]
Clinical treatment programs

0

-

0

0

-

248

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Europe [Member]
Clinical treatment programs

0

-

0

0

-

119

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-